- 2 hrs ago German Actor Hardy Krüger Passes Away At 93: A Look At His Life And Career
- 7 hrs ago Easy Breakfast Recipe: How To Make Split Black Gram Or Urad Dal Dosa
- 11 hrs ago Remodelling Your Kitchen? Here Are 8 Must-Haves To Take It To The Next Level
- 13 hrs ago Covid-Flu Combined Booster Shot Possible Late 2023: Moderna
- News Chidambaram should resign if Congress fails to oust BJP in Goa: TMC
- Finance Cryptos Show Strength; Cosmos Outperforms, Tether, Cardano Weak
- Sports BCCI Central Contracts: Will non-performers Ajinkya Rahane, Cheteshwar Pujara be able to remain in Grade A?
- Movies Arun Verma, Who Worked Alongside Salman Khan In Kick, Passes Away At 62
- Technology Windows 11 Gets New Task Manager: Goodbye Legacy Task Manager
- Education ICSI CS Foundation CSEET Result 2022 Declared, Steps To Check ICSI CSEET CS Foundation Results On icsi.edu
- Automobiles Petrol Prices Slashed In Jharkhand: Rs 25 per Litre Subsidy
- Travel Amazing Places To Visit In Assam In Winter Of 2022
The Indian Council of Medical Research (ICMR)'s National Task Force for COVID-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for COVID-19 as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis. This anti-Covid pill got the Drug Regulator General of India's approval on December 28 for restricted use in emergencies.
"Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns," an official source told PTI.
Indian Council of Medical Research (ICMR) chief Dr Balram Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for treatment.
"We have to remember that this drug has major safety concerns. It can cause teratogenicity, mutagenicity and cartilage damage. It can damage the muscles also.
"Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," he had said.
The UK Medicines and Healthcare products Regulatory Agency had on December 4 granted approval for Molnupiravir under special conditions for treatment of mild to moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
USFDA on December 23 granted Emergency Use Authorisation for the drug for treating mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalization or death, and for whom alternative treatment options are not accessible or clinically appropriate.
According to conditions, the drug should be sold by retail only under the prescription of medical specialists and the recommended dose should be 800 mg twice daily for five days.
- healthCOVID Antiviral Drug Molnupiravir Has Major Safety Concerns: ICMR Chief Dr Balram Bhargava
- disorders cureCOVID Antiviral Oral Pill Molnupiravir: Know Price, Dosage, Side Effects And Other Details
- healthSun Pharma Gets DCGI Nod To Market Molnupiravir For COVID-19 Treatment
- healthPanel Recommends EUA For Covid-19 Vaccines Covovax, Corbevax And Anti-Covid Pill Molnupiravir
- healthCovid-Flu Combined Booster Shot Possible Late 2023: Moderna
- healthNot Possible To End This Virus; Pandemic Viruses End Up Becoming Part Of Ecosystem: WHO Official
- basicsPregnant, Lactating Mothers Made Aware Of Side Effects Of Covid-19 Vaccination, Centre Tell SC
- healthFailure To Vaccinate Everyone Will Give Rise To New Variants: UN Chief
- healthCOVID-19 Treatment: Govt Issues Revised Guidelines On Use Of Drugs, Therapies
- healthAsymptomatic Animal Handlers Transmit COVID Delta Variant To Lions At Zoo In South Africa: Study
- healthDr Angelique Coetzee: Don’t Look At Your Positivity Rate, Look At How Many People Admitted In ICU
- healthCOVID-19: Why T Cell Vaccines Could Be The Key To Long-Term Immunity